Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV vaccine for treatment of CIN1
IRCT20230522058253N2Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 3 trial of quadrivalent human papillomavirus vaccine in cervical intraepithelial neoplasia (CIN), sponsored by Hamadan University of Medical Sciences. Started Jul 2022; status: completed.
02
Drugs
quadrivalent human papillomavirus vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on IRCT20230522058253N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230522058253N2.